TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
10x Genomics Sweden AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
98,309
|
179,704
|
171,257 |
| Financial expenses |
51
|
210
|
5 |
| Earnings before taxes |
41,629
|
103,325
|
90,766 |
| EBITDA |
42,372
|
109,743
|
97,135 |
| Total assets |
69,093
|
248,675
|
174,010 |
| Current assets |
69,093
|
235,886
|
155,154 |
| Current liabilities |
16,351
|
23,675
|
37,559 |
| Equity capital |
52,742
|
225,001
|
136,451 |
| - share capital |
32
|
34
|
33 |
| Employees (average) |
19
|
39
|
45 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
76.3%
|
90.5%
|
78.4% |
| Turnover per employee |
5,174
|
4,608
|
3,806 |
| Profit as a percentage of turnover |
42.3%
|
57.5%
|
53.0% |
| Return on assets (ROA) |
60.3%
|
41.6%
|
52.2% |
| Current ratio |
422.6%
|
996.4%
|
413.1% |
| Return on equity (ROE) |
78.9%
|
45.9%
|
66.5% |
| Change turnover |
-75,451
|
7,564
|
64,889 |
| Change turnover % |
-43%
|
4%
|
61% |
| Chg. No. of employees |
-20
|
-6
|
7 |
| Chg. No. of employees % |
-51%
|
-13%
|
18% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.